Literature DB >> 7631138

TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action.

F M Brennan1, D L Gibbons, A P Cope, P Katsikis, R N Maini, M Feldmann.   

Abstract

We have proposed the hypothesis that tumour necrosis factor alpha (TNF-alpha) has a pivotal role in the pathogenesis of rheumatoid arthritis, based on in vitro observations that in RA synovial joint cell cultures removal of TNF-alpha, inhibited other potentially pathogenic cytokines such as the equally proinflammatory cytokine interleukin 1 (IL-1) and the macrophage activating factor, GM-CSF. Here we describe that in both rheumatoid (RA) and osteoarthritic (OA) synovial cultures there is a homeostatic mechanism to regulate the activities of TNF-alpha. This concept is based on several observations. First in these synovial joint cell cultures the substantial discrepancy between the levels of bioactive and immunoreactive TNF-alpha indicates the presence of an inhibitor. Second, TNF binding proteins are produced spontaneously, which are the soluble variants of surface p75 and p55 TNF receptor. The amount of soluble TNF receptors (sTNF-R) produced varied between cultures; p75 sTNF-R was more abundant than p55 sTNF-R (as detected by ELISA), and both were produced at higher levels by RA synovial joint cells in culture, compared to OA cultures. These TNF binding proteins act as endogenous inhibitors of TNF-alpha, since blocking their activity in synovial joint cell culture supernatants with MoAb to p55 and p75 sTNF-R enhanced their cytotoxic activity in the TNF bioassay. The regulation of production of these sTNF-R in synovial joint cell cultures is important as the balance between TNF-alpha and sTNF-R production may determine the outcome of the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631138     DOI: 10.1111/j.1365-3083.1995.tb03639.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

Review 1.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Authors:  C K Edwards
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Etanercept: therapeutic use in patients with rheumatoid arthritis.

Authors:  L Garrison; N D McDonnell
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  Inflammaging decreases adaptive and innate immune responses in mice and humans.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Biogerontology       Date:  2015-04-29       Impact factor: 4.277

4.  Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis.

Authors:  L Armstrong; N M Foley; A B Millar
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

5.  Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy.

Authors:  G A Limb; H Soomro; S Janikoun; R D Hollifield; J Shilling
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

6.  Cytokines in Mycoplasma hyorhinis-induced arthritis in pigs bred selectively for high and low immune responses.

Authors:  N R Jayagopala Reddy; B N Wilkie; P Borgs; B A Mallard
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.

Authors:  L M Williams; D L Gibbons; A Gearing; R N Maini; M Feldmann; F M Brennan
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

8.  Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis.

Authors:  Christopher J Edwards; Jeffrey L Feldman; Jonathan Beech; Kathleen M Shields; Jennifer A Stover; William L Trepicchio; Glenn Larsen; Brian Mj Foxwell; Fionula M Brennan; Marc Feldmann; Debra D Pittman
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

Review 9.  [Rheumatoid arthritis: new molecular and cellular aspects].

Authors:  O Distler; U Müller-Ladner; J Schölmerich; R E Gay; S Gay
Journal:  Med Klin (Munich)       Date:  1999-12-15

Review 10.  New therapeutic targets for rheumatoid arthritis.

Authors:  H J Dinant; B A Dijkmans
Journal:  Pharm World Sci       Date:  1999-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.